News

Is Eli Lilly Stock a Buy? Here's What the Market Isn't Pricing in Yet.

Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...

It’s rude to ask if someone is taking Ozempic. Here’s why.

Twelve percent of adults in the United States have taken them at some point, according to a 2024 KFF Health Tracking Poll, ...